CFR Talks Price

Chile’s CFR Pharmaceuticals is heard aiming for a yield in the neighborhood of 5.50%-5.75% for a $300m 2022 NC5 bond, with pricing expected as soon as today. Investor interest was heard reaching $1bn as of Wednesday. JPMorgan and Deutsche Bank are managing the BBB minus/BB+ deal. Fresh off of its domestic DCM debut, the pharmaceutical company now turns abroad, raising funds for the $562m acquisition of Colombia’s Laboratorio Franco Colombiano (Lafrancol) agreed in August. CFR raised UF3m ($142m) through a domestic 2033 bond earlier this month.